|
Q4 2017
Filed on Feb 14, 2018
|
10
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
200
|
$50.3 - $64.39
$10.1K - $12.9K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
386
|
$12.25 - $12.89
$4.73K - $4.98K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
200
|
$9.47 - $19.59
$1.89K - $3.92K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
4,876
|
N/A
|
|
Oppenheimer Rev Weightd ETF
|
Q4 2017
Filed on Feb 14, 2018
|
1,219
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
1,480
|
$35.54 - $37.2
$52.6K - $55.1K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
498
|
$30.68 - $35.37
$15.3K - $17.6K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
102
|
$62.76 - $66.17
$6.4K - $6.75K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
500
|
$13.36 - $20.73
$6.68K - $10.4K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
600
|
$12.65 - $16.75
$7.59K - $10.1K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
150
|
$11.23 - $19.1
$1.68K - $2.87K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
4,790
|
$37.71 - $44.43
$181K - $213K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
8,000
|
$8.14 - $10.21
$65.1K - $81.7K
|
|
Stemline Therapeutics Inc
|
Q4 2017
Filed on Feb 14, 2018
|
300
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
300
|
$2.18 - $2.81
$654 - $843
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
111
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
100
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
200
|
$37.77 - $47.75
$7.55K - $9.55K
|
|
Keryx Biopharmaceuticals Inc
|
Q4 2017
Filed on Feb 14, 2018
|
10,000
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
219
|
$122.81 - $135.57
$26.9K - $29.7K
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
12,500
|
N/A
|
|
|
Q4 2017
Filed on Feb 14, 2018
|
100
|
$154.99 - $171.74
$15.5K - $17.2K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
1,011
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
5,400
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
38
|
$23.19 - $23.95
$881 - $910
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
640
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
46
|
$36.38 - $47.5
$1.67K - $2.19K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
3
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
150
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
5,170
|
$32.43 - $35.14
$168K - $182K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
300
|
$20.29 - $29.88
$6.09K - $8.96K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
141
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
200
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
300
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
3,170
|
$31.66 - $37.16
$100K - $118K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
30
|
$49.89 - $50.38
$1.5K - $1.51K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
487
|
$38.31 - $42.32
$18.7K - $20.6K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
2,110
|
N/A
|
|
Merrimack Pharmaceuticals In
|
Q3 2017
Filed on Nov 15, 2017
|
300
|
N/A
|
|
Threshold Pharmaceutical Inc
|
Q3 2017
Filed on Nov 15, 2017
|
600
|
N/A
|
|
Orexigen Therapeutics Inc
|
Q3 2017
Filed on Nov 15, 2017
|
50
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
75
|
$5.13 - $6.3
$385 - $473
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
4,885
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
272
|
$53.03 - $64.84
$14.4K - $17.6K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
200
|
$15.81 - $24.01
$3.16K - $4.8K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
200
|
N/A
|
|
Twenty First Centy Fox Inc
|
Q3 2017
Filed on Nov 15, 2017
|
493
|
N/A
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
96
|
$13.96 - $14.48
$1.34K - $1.39K
|
|
|
Q3 2017
Filed on Nov 15, 2017
|
601
|
N/A
|
|